THERAPY-RELATED ACUTE MYELOID LEUKEMIA
Clinical trials for THERAPY-RELATED ACUTE MYELOID LEUKEMIA explained in plain language.
Never miss a new study
Get alerted when new THERAPY-RELATED ACUTE MYELOID LEUKEMIA trials appear
Sign up with your email to follow new studies for THERAPY-RELATED ACUTE MYELOID LEUKEMIA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Leukemia trial hopes to boost chemo with immune drug
Disease control OngoingThis phase 2 trial tests whether adding the drug pomalidomide to standard chemotherapy (daunorubicin and cytarabine liposome) helps people with a newly diagnosed, aggressive form of acute myeloid leukemia (AML) linked to prior bone marrow disorders. About 50 participants will rec…
Matched conditions: THERAPY-RELATED ACUTE MYELOID LEUKEMIA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
Immunotherapy boosts chemo to wipe out hidden leukemia cells
Disease control OngoingThis phase 2 trial tests whether adding the immunotherapy drug pembrolizumab to standard chemotherapy helps people with newly diagnosed acute myeloid leukemia (AML) achieve a deeper remission. About 49 participants will receive either chemo alone or chemo plus pembrolizumab. The …
Matched conditions: THERAPY-RELATED ACUTE MYELOID LEUKEMIA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
Can a drug combo stop AML from coming back?
Disease control OngoingThis phase II trial tests whether a combination of two drugs, azacitidine and venetoclax, can help keep acute myeloid leukemia (AML) in remission after initial treatment. The study enrolls 50 adults whose AML is in first remission but who are not ready for a stem cell transplant.…
Matched conditions: THERAPY-RELATED ACUTE MYELOID LEUKEMIA
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC
-
New drug cocktail aims to stop leukemia relapse after transplant
Disease control OngoingThis phase 2 trial tests whether combining venetoclax and azacitidine after a stem cell transplant can prevent leukemia from returning in high-risk patients. About 100 adults aged 18-75 with certain types of acute leukemia who are in remission after transplant will receive the dr…
Matched conditions: THERAPY-RELATED ACUTE MYELOID LEUKEMIA
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
Experimental drug combo shows promise for Tough-to-Treat leukemia
Disease control OngoingThis study tests whether adding pevonedistat to standard chemotherapy (cytarabine and idarubicin) can improve remission rates in people newly diagnosed with high-risk acute myeloid leukemia (AML). About 53 participants will receive the combination to find the best dose and check …
Matched conditions: THERAPY-RELATED ACUTE MYELOID LEUKEMIA
Phase: PHASE1, PHASE2 • Sponsor: University of Southern California • Aim: Disease control
Last updated Jun 27, 2026 13:01 UTC
-
Immunotherapy combo shows promise against tough blood cancer in seniors
Disease control OngoingThis study tests whether adding an immunotherapy drug (pembrolizumab) to standard chemotherapy (azacitidine and venetoclax) can improve outcomes for older adults with newly diagnosed acute myeloid leukemia (AML) who cannot have intensive chemo. About 60 participants will be rando…
Matched conditions: THERAPY-RELATED ACUTE MYELOID LEUKEMIA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New cocktail of cancer drugs tested for tough leukemia
Disease control OngoingThis early-phase trial tests a combination of three drugs — bortezomib, sorafenib, and decitabine — in patients with acute myeloid leukemia (AML), especially those who are older or have hard-to-treat forms. The main goal is to find the safest dose and see how well patients tolera…
Matched conditions: THERAPY-RELATED ACUTE MYELOID LEUKEMIA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC
-
New drug cocktail aims to beat Hard-to-Treat leukemia
Disease control OngoingThis phase 2 trial is testing a combination of two drugs—CPX-351 (a chemotherapy) and glasdegib (a targeted pill)—in 30 people with acute myeloid leukemia (AML) that is either linked to a prior blood disorder or caused by previous cancer treatment. The main goal is to see how man…
Matched conditions: THERAPY-RELATED ACUTE MYELOID LEUKEMIA
Phase: PHASE2 • Sponsor: University of California, Irvine • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC
-
New drug combo shows promise for Tough-to-Treat leukemia in younger patients
Disease control OngoingThis study tests a chemotherapy drug called CPX-351 in people under 60 with secondary acute myeloid leukemia (AML), a type of leukemia that develops after other blood disorders or cancer treatments. The goal is to see how well the drug can make the cancer disappear or improve blo…
Matched conditions: THERAPY-RELATED ACUTE MYELOID LEUKEMIA
Phase: PHASE2 • Sponsor: Roswell Park Cancer Institute • Aim: Disease control
Last updated Jun 27, 2026 08:05 UTC